Optimized chemical proteomics assay for kinase inhibitor profiling

Journal of Proteome Research

Volumn 14, Issue 3, 2015, Pages 1574-1586

  Médard, Guillaume ^a   Pachl, Fiona ^a   Ruprecht, Benjamin ^a   Klaeger, Susan ^a,b   Heinzlmeir, Stephanie ^a,b   Helm, Dominic ^a   Qiao, Huichao ^a   Ku, Xin ^a   Wilhelm, Mathias ^a   Kuehne, Thomas ^a   Wu, Zhixiang ^a   Dittmann, Antje ^c   Hopf, Carsten ^c   Kramer, Karl ^a   Kuster, Bernhard ^a,b,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Munich Center for Integrated Protein Science   (Germany)

Author keywords

affinity matrix; chemical proteomics; drug profiling; kinase inhibitors; kinobeads

Indexed keywords

CRIZOTINIB; DASATINIB; FASUDIL; FLAVOPIRIDOL; HYDROXYFASUDIL; IBRUTINIB; IMATINIB; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; SUNITINIB; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL LYSATE; CHEMICAL PROTEOMICS; COMPUTER MODEL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; MASS SPECTROMETRY;

MASS SPECTROMETRY; PROTEIN KINASE INHIBITORS; PROTEOMICS;

EID: 84924371112     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr5012608     Document Type: Article

References (67)

1. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nature Rev. Drug Discovery 2002, 1 (4) 309-315
2. Manning, G.; Whyte, D.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science (New York, N.Y.) 2002, 298 (5600) 1912-1934
3. Greenman, C.; Stephens, P.; Smith, R.; Dalgliesh, G.; Hunter, C.; Bignell, G.; Davies, H.; Teague, J.; Butler, A.; Stevens, C.; Edkins, S.; O'Meara, S.; Vastrik, I.; Schmidt, E.; Avis, T.; Barthorpe, S.; Bhamra, G.; Buck, G.; Choudhury, B.; Clements, J.; Cole, J.; Dicks, E.; Forbes, S.; Gray, K.; Halliday, K.; Harrison, R.; Hills, K.; Hinton, J.; Jenkinson, A.; Jones, D.; Menzies, A.; Mironenko, T.; Perry, J.; Raine, K.; Richardson, D.; Shepherd, R.; Small, A.; Tofts, C.; Varian, J.; Webb, T.; West, S.; Widaa, S.; Yates, A.; Cahill, D.; Louis, D.; Goldstraw, P.; Nicholson, A.; Brasseur, F.; Looijenga, L.; Weber, B.; Chiew, Y.-E.; DeFazio, A.; Greaves, M.; Green, A.; Campbell, P.; Birney, E.; Easton, D.; Chenevix-Trench, G.; Tan, M.-H.; Khoo, S.; Teh, B.; Yuen, S.; Leung, S.; Wooster, R.; Futreal, P.; Stratton, M. Patterns of somatic mutation in human cancer genomes Nature 2007, 446 (7132) 153-158
4. Karaman, M.; Herrgard, S.; Treiber, D.; Gallant, P.; Atteridge, C.; Campbell, B.; Chan, K.; Ciceri, P.; Davis, M.; Edeen, P.; Faraoni, R.; Floyd, M.; Hunt, J.; Lockhart, D.; Milanov, Z.; Morrison, M.; Pallares, G.; Patel, H.; Pritchard, S.; Wodicka, L.; Zarrinkar, P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26 (1) 127-132
5. Huang, D.; Zhou, T.; Lafleur, K.; Nevado, C.; Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis Bioinformatics (Oxford, England) 2009, 26 (2) 198-204
6. Davis, M.; Hunt, J.; Herrgard, S.; Ciceri, P.; Wodicka, L.; Pallares, G.; Hocker, M.; Treiber, D.; Zarrinkar, P. Comprehensive analysis of kinase inhibitor selectivity Nature Biotechnol. 2011, 29 (11) 1046-1051
7. Morphy, R. Selectively nonselective kinase inhibition: striking the right balance J. Med. Chem. 2010, 53 (4) 1413-1437
8. Ashburn, T.; Thor, K. Drug repositioning: identifying and developing new uses for existing drugs Nature Rev. Drug Discovery 2004, 3 (8) 673-683
9. Dakshanamurthy, S.; Issa, N.; Assefnia, S.; Seshasayee, A.; Peters, O.; Madhavan, S.; Uren, A.; Brown, M.; Byers, S. Predicting new indications for approved drugs using a proteochemometric method J. Med. Chem. 2012, 55 (15) 6832-6848
10. Lee, J.; Uhlik, M.; Moxham, C.; Tomandl, D.; Sall, D. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy J. Med. Chem. 2012, 55 (10) 4527-4538
11. Zheng, W.; Thorne, N.; McKew, J. Phenotypic screens as a renewed approach for drug discovery Drug Discovery Today 2013, 18 (21-22) 1067-73
12. Moffat, J. G.; Rudolph, J.; Bailey, D. Phenotypic screening in cancer drug discovery-past, present and future Nature Rev. Drug Discovery 2014, 13 (8) 588-602
13. Terstappen, G.; Schlüpen, C.; Raggiaschi, R.; Gaviraghi, G. Target deconvolution strategies in drug discovery Nature Rev. Drug Discovery 2007, 6 (11) 891-903
14. Ziegler, S.; Pries, V.; Hedberg, C.; Waldmann, H. Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack Angew. Chem., Int. Ed. Engl. 2013, 52, 2744-2792
15. Drewry, D. H.; Bamborough, P.; Schneider, K.; Smith, G. K. The Kinome and its Impact on Medicinal Chemistry Kinase Drug Discovery 2012, 1-29
16. Gao, Y.; Davies, S.; Augustin, M.; Woodward, A.; Patel, U.; Kovelman, R.; Harvey, K. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery Biochem. J. 2013, 451 (2) 313-328
17. Schirle, M.; Bantscheff, M.; Kuster, B. Mass spectrometry-based proteomics in preclinical drug discovery Chemistry & biology 2012, 19 (1) 72-84
18. Rix, U.; Superti-Furga, G. Target profiling of small molecules by chemical proteomics Nat. Chem. Biol. 2009, 5 (9) 616-624
19. Xiao, Y.; Wang, Y., Global discovery of protein kinases and other nucleotide-binding proteins by mass spectrometry. Mass Spectrom Rev., DOI: 10.1002/mas.21447.
20. Rix, U.; Hantschel, O.; Dürnberger, G.; Remsing Rix, L.; Planyavsky, M.; Fernbach, N.; Kaupe, I.; Bennett, K.; Valent, P.; Colinge, J.; Köcher, T.; Superti-Furga, G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 2007, 110 (12) 4055-4063
21. Rix, U.; Remsing Rix, L.; Terker, A.; Fernbach, N.; Hantschel, O.; Planyavsky, M.; Breitwieser, F.; Herrmann, H.; Colinge, J.; Bennett, K.; Augustin, M.; Till, J.; Heinrich, M.; Valent, P.; Superti-Furga, G. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells Leukemia 2010, 24 (1) 44-50
22. Ong, S. E.; Schenone, M.; Margolin, A. A.; Li, X.; Do, K.; Doud, M. K.; Mani, D. R.; Kuai, L.; Wang, X.; Wood, J. L.; Tolliday, N. J.; Koehler, A. N.; Marcaurelle, L. A.; Golub, T. R.; Gould, R. J.; Schreiber, S. L.; Carr, S. A. Identifying the proteins to which small-molecule probes and drugs bind in cells Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (12) 4617-22
23. Patricelli, M.; Nomanbhoy, T.; Wu, J.; Brown, H.; Zhou, D.; Zhang, J.; Jagannathan, S.; Aban, A.; Okerberg, E.; Herring, C.; Nordin, B.; Weissig, H.; Yang, Q.; Lee, J.-D.; Gray, N.; Kozarich, J. In situ kinase profiling reveals functionally relevant properties of native kinases Chem. Biol. 2011, 18 (6) 699-710
24. Xiao, Y.; Guo, L.; Wang, Y. A Targeted Quantitative Proteomics Strategy for Global Kinome Profiling of Cancer Cells and Tissues Mol. Cell Proteomics 2014, 13 (4) 1065-75
25. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V. r.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nature Biotechnol. 2007, 25 (9) 1035-1044
26. Lemeer, S.; Zörgiebel, C.; Ruprecht, B.; Kohl, K.; Kuster, B. Comparing Immobilized Kinase Inhibitors and Covalent ATP Probes for Proteomic Profiling of Kinase Expression and Drug Selectivity J. Proteome Res. 2013, 12 (4) 1723-1731
27. Duncan, J.; Whittle, M.; Nakamura, K.; Abell, A.; Midland, A.; Zawistowski, J.; Johnson, N.; Granger, D.; Jordan, N.; Darr, D.; Usary, J.; Kuan, P.-F.; Smalley, D.; Major, B.; He, X.; Hoadley, K.; Zhou, B.; Sharpless, N.; Perou, C.; Kim, W.; Gomez, S.; Chen, X.; Jin, J.; Frye, S.; Earp, H.; Graves, L.; Johnson, G. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer Cell 2012, 149 (2) 307-321
28. Zhang, L.; Holmes, I.; Hochgräfe, F.; Walker, S.; Ali, N.; Humphrey, E.; Wu, J.; de Silva, M.; Kersten, W.; Connor, T.; Falk, H.; Allan, L.; Street, I.; Bentley, J.; Pilling, P.; Monahan, B.; Peat, T.; Daly, R. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling J. Proteome Res. 2013, 12 (7) 3104-3116
29. Bantscheff, M.; Lemeer, S.; Savitski, M.; Kuster, B. Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present Anal. Bioanal. Chem. 2012, 404 (4) 939-965
30. Knapp, S.; Arruda, P.; Blagg, J.; Burley, S.; Drewry, D.; Edwards, A.; Fabbro, D.; Gillespie, P.; Gray, N.; Kuster, B.; Lackey, K.; Mazzafera, P.; Tomkinson, N.; Willson, T.; Workman, P.; Zuercher, W. A public-private partnership to unlock the untargeted kinome Nat. Chem. Biol. 2013, 9 (1) 3-6
31. Oppermann, F. S.; Gnad, F.; Olsen, J. V.; Hornberger, R.; Greff, Z.; Keri, G.; Mann, M.; Daub, H. Large-scale proteomics analysis of the human kinome Mol. Cell Proteomics 2009, 8 (7) 1751-64
32. Schirle, M.; Petrella, E.; Brittain, S.; Schwalb, D.; Harrington, E.; Cornella-Taracido, I.; Tallarico, J. Kinase inhibitor profiling using chemoproteomics Methods Mol. Biol. (Clifton, N.J.) 2012, 795, 161-177
33. Pachl, F.; Plattner, P.; Ruprecht, B.; Médard, G.; Sewald, N.; Kuster, B. Characterization of a Chemical Affinity Probe Targeting Akt Kinases J. Proteome Res. 2013, 12, 3792-3800
34. Ku, X.; Heinzlmeir, S.; Helm, D.; Médard, G.; Kuster, B. New Affinity Probe Targeting VEGF Receptors for Kinase Inhibitor Selectivity Profiling by Chemical Proteomics J. Proteome Res. 2014, 13 (5) 2445-2452
35. Gholami, A.; Hahne, H.; Wu, Z.; Auer, F.; Meng, C.; Wilhelm, M.; Kuster, B. Global Proteome Analysis of the NCI-60 Cell Line Panel Cell Rep. 2013, 4 (3) 609-620
36. https://github.com/ThomasKuehne/kinaseblender.
37. Ishii, N.; Maier, D.; Merlo, A.; Tada, M.; Sawamura, Y.; Diserens, A. C.; Van Meir, E. G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines Brain Pathol. 1999, 9 (3) 469-79
38. Ku, X.; Heinzlmeir, S.; Liu, X.; Médard, G.; Kuster, B. A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors J. Proteomics 2014, 96 (16) 44-55
39. Hahne, H.; Pachl, F.; Ruprecht, B.; Maier, S.; Klaeger, S.; Helm, D.; Médard, G.; Wilm, M.; Lemeer, S.; Kuster, B. DMSO enhances electrospray response, boosting sensitivity of proteomic experiments Nat. Methods 2013, 10, 989-991
40. Cox, J.; Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification Nat. Biotechnol. 2008, 26 (12) 1367-72
41. Cox, J.; Hein, M. Y.; Luber, C. A.; Paron, I.; Nagaraj, N.; Mann, M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ Mol. Cell Proteomics 2014, 13 (9) 2513-26
42. Sharma, K.; Weber, C.; Bairlein, M.; Greff, Z.; Kéri, G.; Cox, J.; Olsen, J.; Daub, H. Proteomics strategy for quantitative protein interaction profiling in cell extracts Nat. Methods 2009, 6 (10) 741-744
43. Fabian, M.; Biggs, W.; Treiber, D.; Atteridge, C.; Azimioara, M.; Benedetti, M.; Carter, T.; Ciceri, P.; Edeen, P.; Floyd, M.; Ford, J.; Galvin, M.; Gerlach, J.; Grotzfeld, R.; Herrgard, S.; Insko, D.; Insko, M.; Lai, A.; Lélias, J.-M.; Mehta, S.; Milanov, Z.; Velasco, A.; Wodicka, L.; Patel, H.; Zarrinkar, P.; Lockhart, D. A small molecule-kinase interaction map for clinical kinase inhibitors Nature Biotechnol. 2005, 23 (3) 329-336
44. Kim, K. S.; Kimball, S. D.; Misra, R. N.; Rawlins, D. B.; Hunt, J. T.; Xiao, H. Y.; Lu, S.; Qian, L.; Han, W. C.; Shan, W.; Mitt, T.; Cai, Z. W.; Poss, M. A.; Zhu, H.; Sack, J. S.; Tokarski, J. S.; Chang, C. Y.; Pavletich, N.; Kamath, A.; Humphreys, W. G.; Marathe, P.; Bursuker, I.; Kellar, K. A.; Roongta, U.; Batorsky, R.; Mulheron, J. G.; Bol, D.; Fairchild, C. R.; Lee, F. Y.; Webster, K. R. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities J. Med. Chem. 2002, 45 (18) 3905-27
45. Lu, H.; Chang, D. J.; Baratte, B.; Meijer, L.; Schulze-Gahmen, U. Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin J. Med. Chem. 2005, 48 (3) 737-43
46. Huber, K. V.; Salah, E.; Radic, B.; Gridling, M.; Elkins, J. M.; Stukalov, A.; Jemth, A. S.; Gokturk, C.; Sanjiv, K.; Stromberg, K.; Pham, T.; Berglund, U. W.; Colinge, J.; Bennett, K. L.; Loizou, J. I.; Helleday, T.; Knapp, S.; Superti-Furga, G. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy Nature 2014, 508 (7495) 222-7
47. Anastassiadis, T.; Deacon, S.; Devarajan, K.; Ma, H.; Peterson, J. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nature Biotechnol. 2011, 29 (11) 1039-1045
48. Kitagawa, D.; Yokota, K.; Gouda, M.; Narumi, Y.; Ohmoto, H.; Nishiwaki, E.; Akita, K.; Kirii, Y. Activity-based kinase profiling of approved tyrosine kinase inhibitors Genes Cells 2013, 18 (2) 110-22
49. Jester, B.; Gaj, A.; Shomin, C.; Cox, K.; Ghosh, I. Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen J. Med. Chem. 2012, 55 (4) 1526-1537
50. Morwick, T.; Buttner, F. H.; Cywin, C. L.; Dahmann, G.; Hickey, E.; Jakes, S.; Kaplita, P.; Kashem, M. A.; Kerr, S.; Kugler, S.; Mao, W.; Marshall, D.; Paw, Z.; Shih, C. K.; Wu, F.; Young, E. Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase J. Med. Chem. 2010, 53 (2) 759-77
51. Wu, F.; Buttner, F. H.; Chen, R.; Hickey, E.; Jakes, S.; Kaplita, P.; Kashem, M. A.; Kerr, S.; Kugler, S.; Paw, Z.; Prokopowicz, A.; Shih, C. K.; Snow, R.; Young, E.; Cywin, C. L. Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account Bioorg. Med. Chem. Lett. 2010, 20 (11) 3235-9
52. Uehata, M.; Ishizaki, T.; Satoh, H.; Ono, T.; Kawahara, T.; Morishita, T.; Tamakawa, H.; Yamagami, K.; Inui, J.; Maekawa, M.; Narumiya, S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 1997, 389 (6654) 990-4
53. Rikitake, Y.; Kim, H. H.; Huang, Z.; Seto, M.; Yano, K.; Asano, T.; Moskowitz, M. A.; Liao, J. K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection Stroke 2005, 36 (10) 2251-7
54. Jacobs, M.; Hayakawa, K.; Swenson, L.; Bellon, S.; Fleming, M.; Taslimi, P.; Doran, J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity J. Biol. Chem. 2006, 281 (1) 260-8
55. Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (29) 13075-80
56. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin. Cancer Res. 2003, 9 (1) 327-37
57. Cui, J. J.; Tran-Dubé, M.; Shen, H.; Nambu, M.; Kung, P. P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54 (18) 6342-63
58. Wen, Q.; Goldenson, B.; Silver, S. J.; Schenone, M.; Dancik, V.; Huang, Z.; Wang, L. Z.; Lewis, T. A.; An, W. F.; Li, X.; Bray, M. A.; Thiollier, C.; Diebold, L.; Gilles, L.; Vokes, M. S.; Moore, C. B.; Bliss-Moreau, M.; Verplank, L.; Tolliday, N. J.; Mishra, R.; Vemula, S.; Shi, J.; Wei, L.; Kapur, R.; Lopez, C. K.; Gerby, B.; Ballerini, P.; Pflumio, F.; Gilliland, D. G.; Goldberg, L.; Birger, Y.; Izraeli, S.; Gamis, A. S.; Smith, F. O.; Woods, W. G.; Taub, J.; Scherer, C. A.; Bradner, J. E.; Goh, B. C.; Mercher, T.; Carpenter, A. E.; Gould, R. J.; Clemons, P. A.; Carr, S. A.; Root, D. E.; Schreiber, S. L.; Stern, A. M.; Crispino, J. D. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL Cell 2012, 150 (3) 575-89
59. Satoh, S.; Utsunomiya, T.; Tsurui, K.; Kobayashi, T.; Ikegaki, I.; Sasaki, Y.; Asano, T. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage Life Sci. 2001, 69 (12) 1441-53
60. Shibuya, M.; Suzuki, Y.; Sugita, K.; Saito, I.; Sasaki, T.; Takakura, K.; Nagata, I.; Kikuchi, H.; Takemae, T.; Hidaka, H. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial J. Neurosurg. 1992, 76 (4) 571-7
61. Bender, C.; Ullrich, A. PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines Int. J. Cancer 2012, 131 (2) E45-E55
62. Li, X.; Iomini, C.; Hyink, D.; Wilson, P. D. PRKX critically regulates endothelial cell proliferation, migration, and vascular-like structure formation Dev. Biol. 2011, 356 (2) 475-85
63. Ying, H.; Biroc, S. L.; Li, W. W.; Alicke, B.; Xuan, J. A.; Pagila, R.; Ohashi, Y.; Okada, T.; Kamata, Y.; Dinter, H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models Mol. Cancer Ther 2006, 5 (9) 2158-64
64. Deng, L.; Li, G.; Li, R.; Liu, Q.; He, Q.; Zhang, J. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo Cancer Biol. Ther 2010, 9 (11) 875-84
65. Brosch, M.; Yu, L.; Hubbard, T.; Choudhary, J. Accurate and sensitive peptide identification with Mascot Percolator J. Proteome Res. 2009, 8 (6) 3176-81
66. Ritz, C. Toward a unified approach to dose-response modeling in ecotoxicology Environ. Toxicol. Chem. 2010, 29 (1) 220-9
67. Wilhelm, M.; Schlegl, J.; Hahne, H.; Moghaddas Gholami, A.; Lieberenz, M.; Savitski, M. M.; Ziegler, E.; Butzmann, L.; Gessulat, S.; Marx, H.; Mathieson, T.; Lemeer, S.; Schnatbaum, K.; Reimer, U.; Wenschuh, H.; Mollenhauer, M.; Slotta-Huspenina, J.; Boese, J. H.; Bantscheff, M.; Gerstmair, A.; Faerber, F.; Kuster, B. Mass-spectrometry-based draft of the human proteome Nature 2014, 509 (7502) 582-7